GNPX — Genprex Share Price
0.000.00%
Last trade - 00:00- $7.55m
- $4.08m
- 13
- 16
- 42
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.95 | ||
| Price to Tang. Book | 3.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -495% | ||
| Return on Equity | -307.08% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Directors
- J. Rodney Varner CHM (63)
- Ryan Confer CFO (39)
- Catherine Vaczy EVP (59)
- Hemant Kumar CTO (59)
- Mark Berger OTH (67)
- Brent Longnecker IND (64)
- Jose Moreno Toscano IND (48)
- William Wilson IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 1st, 2009
- Public Since
- March 29th, 2018
- No. of Shareholders
- 171
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 29,007,995
- Address
- 3300 Bee Cave Road, Suite 650-227, AUSTIN, 78746
- Web
- https://www.genprex.com/
- Phone
- +1 5125377997
- Auditors
- WithumSmith Brown PC
Upcoming Events for GNPX
Q2 2025 Genprex Inc Earnings Release
Q3 2025 Genprex Inc Earnings Release
Similar to GNPX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Genprex share price?
As of Today at 11:48 UTC, shares in Genprex are trading at $0.26. This share price information is delayed by 15 minutes.
How has the Genprex share price performed this year?
Shares in Genprex last closed at $0.26 and the price had moved by -86.37% over the past 365 days. In terms of relative price strength the Genprex share price has underperformed the S&P500 Index by -87.82% over the past year.
What are the analyst and broker recommendations for Genprex?
The overall consensus recommendation for Genprex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genprex dividend yield?
Genprex does not currently pay a dividend.
Does Genprex pay a dividend?
Genprex does not currently pay a dividend.
When does Genprex next pay dividends?
Genprex does not currently pay a dividend.
How do I buy Genprex shares?
To buy shares in Genprex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genprex?
As of the previous close price of $0.26, shares in Genprex had a market capitalisation of $7.55m.
Where are Genprex shares listed?
Here are the trading details for Genprex:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GNPX
What kind of share is Genprex?
Based on an overall assessment of its quality, value and momentum Genprex is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genprex share price forecast for 2025?
The analyst consensus target price for shares in Genprex is $7.50. That is 2781.29% above the last closing price of $0.26.
Analysts covering Genprex currently have a consensus Earnings Per Share (EPS) forecast of -$1.25 for the next financial year.
Find out moreWhat is the trend in the Genprex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genprex. Over the past six months, its share price has underperformed the S&P500 Index by -70.18%.
As of the last closing price of $0.26, shares in Genprex were trading -59.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genprex PE Ratio?
The Genprex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genprex?
Genprex's management team is headed by:
- J. Rodney Varner - CHM
- Ryan Confer - CFO
- Catherine Vaczy - EVP
- Hemant Kumar - CTO
- Mark Berger - OTH
- Brent Longnecker - IND
- Jose Moreno Toscano - IND
- William Wilson - IND